Net profit of Zydus Lifesciences rose 298.62% to Rs 1182.30 crore in the quarter ended March 2024 as against Rs 296.60 crore during the previous quarter ended March 2023. Sales rose 10.59% to Rs 5366.40 crore in the quarter ended March 2024 as against Rs 4852.50 crore during the previous quarter ended March 2023.For the full year,net profit rose 96.88% to Rs 3859.50 crore in the year ended March 2024 as against Rs 1960.30 crore during the previous year ended March 2023. Sales rose 12.70% to Rs 19021.50 crore in the year ended March 2024 as against Rs 16877.80 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales5366.404852.50 11 19021.5016877.80 13 OPM %30.3825.88 -28.3122.87 - PBDT1752.301265.70 38 5587.203916.60 43 PBT1547.001087.10 42 4823.103193.90 51 NP1182.30296.60 299 3859.501960.30 97 Powered by Capital Market - Live News

Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 17 May 2024Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Dapsone Gel, 7.5%, (USRLD: Aczone� Gel 7.5%). Dapsone Gel is used to treat acne and will be manufactured at the group`s topical manufacturing facility at Changodar, Ahmedabad (India).Dapsone Gel, 7.5% had annual sales of USD 35.8 mn in the United States (IQVIA MAT March 24).Powered by Capital Market - Live News

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), and Eiger BioPharmaceuticals, Inc. (OTC: EIGRQ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced the closing of the sale of Eiger`s Zokinvy� (lonafarnib) program to Sentynl. Zokinvy� is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) to target the cause and symptoms of Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), and Processing-Deficient Progeroid Laminopathies (PDPL) in young people 12 months of age and older. Collectively known as Progeria, HGPS and PDPL are ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. Following its U.S. approval in 2020, Zokinvy� secured approval in the European Union and Great Britain (2022) and in Japan (January 2024).Powered by Capital Market - Live News

Zydus Lifesciences announced that the USFDA conducted an inspection at the Injectable Manufacturing site situated at Jarod, near Vadodara. The inspection was conducted from 15 April to 23 April 2024. The inspection closed with 10 observations. The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner. Powered by Capital Market - Live News